# Which AI Vendor Security Checks Should Healthcare Teams Require in 2026?

hygiea.tech · September 24, 2026

> What healthcare AI vendor security actually means Healthcare AI vendor security is the set of technical, contractual, and operational controls used to...

## What healthcare AI vendor security actually means

Healthcare AI vendor security is the set of technical, contractual, and operational controls used to protect patient information, clinical workflows, and critical services when an outside company supplies or operates an AI system. It covers more than whether the vendor has a security certification. A healthcare organization must also determine what data the AI receives, whether it can create new access, what happens when the model or vendor changes, and how the organization would detect or stop a harmful event. The relevant question is not whether AI is safe in the abstract, but whether this particular deployment can be used, monitored, and terminated within the organization's risk tolerance. The answer is therefore a structured due-diligence process, not a single certificate or questionnaire.

**Also worth reading:** [What Will Healthcare Data Security Standards Mean for Healthcare Organizations in 2027?](https://hygiea.tech/knowledge/what_will_healthcare_data_security_standards_mean_for_healthcare_organizations_in_2027.php) · [How Does Healthcare Hygiene Software Security Compare Across Enterprise Platforms in 2026?](https://hygiea.tech/knowledge/how_does_healthcare_hygiene_software_security_compare_across_enterprise_platforms_in_2026.php) · [How Does Clinical IoT Vulnerability Management Differ from Standard IT Security in Healthcare?](https://hygiea.tech/knowledge/how_does_clinical_iot_vulnerability_management_differ_from_standard_it_security_in_healthcare.php)

A useful review begins by identifying the exact product, service, and data flow. The vendor might operate a medical scribe, scheduling assistant, patient-engagement chatbot, coding tool, imaging workflow, or administrative agent that connects to an electronic health record. Each product can have a different hosting model, set of subprocessors, retention policy, and level of autonomy. A general statement that a company uses enterprise-grade AI security is not enough to support a decision involving protected health information. Healthcare teams should require evidence tied to the named service and the intended use case.

The correct standard depends partly on where the system operates and what information it handles. In the United States, a vendor that creates, receives, maintains, or transmits protected health information on behalf of a covered entity is generally a business associate, which makes a Business Associate Agreement important. If the tool handles no protected health information, HIPAA may not apply to that specific flow, although privacy, professional, contractual, and state requirements may still apply. International deployments may add GDPR, UK GDPR, or other national rules. Security review should therefore combine legal mapping with technical testing rather than treating HIPAA as the only issue.

## Why the risk changed by September 2026

AI introduces risks that ordinary SaaS reviews do not always detect. A conventional application may be vulnerable to weak authentication or an unpatched server, while an AI system can also process untrusted text, follow instructions embedded in documents, expose data through excessive retrieval permissions, or generate confident but incorrect clinical or administrative output. Agentic systems add another layer because they can call tools, write records, send messages, or initiate transactions. The research context points to agent identity as a leading concern for healthcare security leaders, which is consistent with the need to control non-human identities and delegated authority.

The supply-chain pressure is visible in recent reporting cited in the research context. A ShinyHunters-related attack on medical supplier McKesson was reported as affecting 6.4 million records, while the Xsolis incident was reported as affecting 1.4 million people or records and prompting discussion about AI vendor risk. These incidents should not be described as proof that every healthcare AI vendor is unsafe. McKesson, in particular, illustrates how a technology or distribution partner can become a route into a healthcare ecosystem; it is not itself evidence of an AI-specific failure. The practical lesson is that a healthcare organization must review downstream service providers, not only the company presenting the AI interface.

AI development itself is also becoming a security and monitoring issue. The supplied context describes an August 2026 report that OpenAI would slow some research to upgrade security and expand monitoring, and it cites a projected $650 billion in AI data-centre spending. Neither fact establishes a healthcare breach, but both show that compute capacity, model development, and infrastructure growth are advancing faster than many procurement processes. More capable models and more autonomous agents can increase the value of a compromised account. Healthcare buyers should assume that model versions, tool permissions, and monitoring requirements will change, and should negotiate how they will learn about those changes.

## How to map the vendor and determine the applicable rules

Start with a one-page inventory for every proposed use. Record the product name, vendor, hosting location, individual users, departments, patient populations, data types, connected systems, model providers, subprocessors, and business purpose. The inventory should distinguish information that is merely displayed from information that is retained, used for training, logged, transferred, or used to improve another customer's service. It should also identify whether a human reviews the output before it affects care, scheduling, billing, or a patient's access to services. Without that map, a vendor can appear compliant because it never stores data directly, even though its agent has copied data into a ticket, prompt log, or third-party observability service.

The next step is to assign responsibilities. A covered entity or business associate must understand which party determines the purposes and means of processing, which party can access the data, and who responds to an incident. A Business Associate Agreement should address permitted uses, safeguards, subcontractors, individual rights requests, audit evidence, return or destruction of data, and breach cooperation. It should also fit the actual product, rather than relying on a generic agreement that does not mention AI, models, prompts, or subprocessors. Many organizations discover during review that the signed agreement covers hosting but not the model provider, retrieval platform, or monitoring service used by the vendor.

The review should then test the claims against recognized control frameworks. NIST Cybersecurity Framework 2.0 provides a useful structure for governance, identification, protection, detection, response, and recovery, while the NIST AI Risk Management Framework offers a way to address AI-specific risks such as validity, security, privacy, transparency, and misuse. SOC 2 Type II reports can provide independent evidence about selected controls over a period, but SOC 2 is not a HIPAA certification and does not prove that a specific AI use case is safe. ISO 27001, HITRUST, or ISO 42001 may help where an organization needs broader assurance, but the organization must still examine model behavior and clinical workflow effects. The appropriate response to a missing document is a documented risk decision, not an assumption that the control exists.

## A practical due-diligence process for healthcare buyers

The first review stage is document and architecture verification. Ask for the current security overview, data-flow diagram, system architecture, list of AI and cloud subprocessors, model-provider information, encryption design, key-management approach, retention schedule, and incident-response procedure. Confirm whether the vendor uses retrieval-augmented generation, fine-tuning, customer-managed models, local models, or a shared inference service. Each design changes the questions that matter. A system that only sends de-identified scheduling instructions has a different risk profile from one that retrieves full clinical histories and writes directly into the medical record.

The second stage is access and identity validation. Healthcare AI should use individual authentication, multifactor authentication, least privilege, and strong separation between administrative, clinical, and service identities. Agents should receive narrowly scoped credentials rather than inheriting a human user's broad session. Short-lived access tokens, approval gates for sensitive actions, and complete audit logs are more useful than a shared service account with a permanent password. Request proof that the vendor reviews dormant accounts, rotates secrets, logs model and tool calls, and can disable an individual agent without disabling the entire platform. A questionnaire response saying that role-based access exists should be followed by evidence showing what roles can actually do.

The third stage is testing the data boundary. Test whether prompts and retrieved documents can cause the system to reveal another patient's data, whether excessive permissions allow an agent to read unrelated records, and whether logs or support tickets contain protected information. Include adversarial documents, indirect prompt-injection attempts, malformed requests, and attempts to trigger tool calls outside the approved workflow. Evaluate output review and escalation procedures as well as confidentiality. A technically secure system that produces an unreviewed appointment cancellation or clinical summary can still create patient-safety and operational problems. Record the severity, reproducibility, affected data, and compensating control for each finding rather than reducing the result to pass or fail.

The fourth stage is operational rehearsal. Ask how quickly the healthcare organization can revoke the vendor's access, export its audit logs, identify affected records, and obtain preservation evidence. Contractual notification periods should be shorter than the organization's actual needs; a 24- or 72-hour vendor notice may be appropriate for high-risk services, but the agreement should also require continuing updates. Confirm who contacts the vendor during an outage, who decides whether to suspend use, and how a compromised model or credential is distinguished from an ordinary service failure. The review should produce an owner, a date, and an acceptable response for every unresolved issue.

## Comparing deployment and review models

Healthcare organizations rarely have one acceptable AI security option. The choice depends on patient-data sensitivity, clinical impact, available internal expertise, and the ability to monitor the system over time. A larger deployment may justify a formal program, while a smaller organization can use a narrower pilot and a smaller set of integrations. The table compares three common approaches; it is a decision aid rather than a ranking of vendors.

| Feature | Option A: Governed enterprise deployment | Option B: Controlled departmental pilot | Option C: Self-hosted or isolated model |
| --- | --- | --- | --- |
| Best fit | Multiple departments and PHI-bearing workflows | Administrative use with limited data and human review | Highly sensitive data or strict residency requirements |
| Core evidence | Independent assurance, BAA, architecture review, annual testing | Vendor documentation, scoped contract, named security owner | Internal architecture, key management, model operations, independent testing |
| Main advantage | Consistent governance and accountability | Faster learning with a contained blast radius | Greater control over data location and model configuration |
| Main drawback | More cost, review time, and change management | May not reveal enterprise-scale or adversarial failure modes | Requires substantial infrastructure, AI, privacy, and security talent |

Option A is preferable when an AI system influences clinical documentation, patient communication, coding, referrals, or other decisions with a material safety effect. Option B can be sensible for a scheduling assistant that receives only the minimum information and requires staff confirmation before acting. Option C may be considered when the organization has the resources to operate models safely, but self-hosting does not remove model risk, insider risk, or the need for clinical validation. A vendor-managed service can be safer than an internally operated system when the organization lacks reliable monitoring and incident-response capacity. The deciding factor is the evidence for the actual configuration, not the deployment label.

## Agent identity, model behavior, and technical testing

The most important change from traditional SaaS review is the need to treat AI agents as privileged software actors. An agent may combine a model, a tool connector, a retrieval index, an identity, and a workflow permission. If those components are reviewed separately, attackers can exploit the gap between them. A model may be allowed to read a document, a connector may be allowed to search the record system, and a tool may be allowed to send an email; together, they can create a chain that none of the individual components appeared to permit. The security team should therefore draw an authorization map for each agent, not only a network diagram.

Testing should cover both conventional vulnerabilities and AI-specific failure modes. Conventional checks include authentication, authorization, patching, vulnerability management, network segmentation, secrets handling, and cloud configuration. AI-specific checks include prompt injection, sensitive-information disclosure, insecure output handling, poisoned retrieval data, excessive agency, model or adapter compromise, data poisoning, membership or training-data exposure where relevant, and unsafe tool invocation. OWASP guidance for large language-model and generative-AI applications can help structure these tests, but it should be adapted to healthcare workflows. A finding that would be unacceptable in a consumer chatbot may be far more serious when it can change an appointment, disclose a substance-use-disorder record, or alter a clinical note.

Human oversight must be designed, not merely mentioned. The organization should know which outputs require review, who can override the system, how overrides are logged, and what happens when the reviewer is unavailable. Safety operations should include monitoring for unusual access patterns, repeated model refusals, changes in output quality, unexpected tool activity, and user reports. A baseline established during the pilot should be compared with production behavior after each model update. The August 2026 reporting about expanded AI security monitoring supports treating monitoring as a continuing capability, not a one-time assessment. It does not justify assuming that a vendor's monitoring can detect clinical harm on its own.

## Contract terms that matter after approval

A security review should be converted into enforceable obligations. The contract should identify the exact services, data categories, locations, subprocessors, and model providers, and it should prohibit material changes without notice. The vendor should be required to maintain administrative, technical, and physical safeguards appropriate to the data, support individual rights requests, cooperate with regulatory inquiries, and provide audit evidence. It should also state whether the vendor may use customer data to train general or customer-specific models, how long prompts and outputs are retained, and what happens when the contract ends. Silence on these points often leaves the healthcare organization with an uncertain deletion obligation.

Security incident language should be operationally precise. A definition limited to unauthorized access to protected health information may not capture a compromised agent, leaked credentials, poisoned model, fraudulent workflow, or prolonged service outage. The agreement should require notice through a named security channel, a preliminary incident description, evidence preservation, root-cause analysis, remediation plans, and regular updates. The parties should agree on who pays for notification, forensic services, restoration, and vendor-caused third-party claims. Those terms should be reviewed with legal counsel, but security leaders should also confirm that the promised timelines match the organization's response plan.

The contract should address resilience and exit as carefully as confidentiality. Ask about service-level objectives, backup practices, recovery-time objectives, recovery-point objectives, model rollback, and the vendor's dependency on cloud or model providers. The healthcare organization should know how it exports audit logs, prompts, configuration, and workflow metadata, and whether export will remain available after termination. Test a sample exit or migration process during the pilot. A vendor that cannot produce usable logs or transfer the data may create lock-in even if the product itself performs well. This is particularly important where a vendor financing arrangement or rapidly changing infrastructure plan makes continuity uncertain.

## Common mistakes and when organizations should pause

One common mistake is treating a security questionnaire as the review. Questionnaires can identify stated policies, but they rarely test whether an agent can reach records outside its intended scope, whether a prompt can trigger an unsafe action, or whether a subprocessor receives data that the agreement never mentioned. Another mistake is accepting a general certification without mapping its scope, period, exceptions, and service boundaries. SOC 2 coverage for a corporate IT environment does not automatically cover a newly launched healthcare agent. A third mistake is assuming that data minimization solves every issue, because an apparently small input can still contain highly sensitive information or grant access to a large backend.

Healthcare teams should pause procurement or expansion when the vendor cannot identify the data flow, refuses to name material subprocessors, will not sign the required agreement, or cannot explain who controls production access. They should also pause when a high-impact use case has no human reviewer, no audit trail, or no tested shutdown mechanism. A finding that permits cross-patient retrieval, credential sharing, arbitrary code execution, or unrestricted write access should normally be treated as a stop condition. Organizations can accept some residual risk, but only after documenting the affected patients, likely harm, compensating controls, expiration date, and person authorized to accept it.

Timing matters because AI systems often enter healthcare through a pilot rather than a formal replacement project. Review security before the first production connection, before adding a new agent, and before a model or subprocessor changes. Repeat the review at least annually for ordinary services and more often after a material architecture, ownership, hosting, or model change. The supplied context includes healthcare leaders describing a fatal cyber incident as inevitable, but inevitability is not a useful control objective. It is better translated into concrete readiness measures: an inventory coverage target of 100% for production AI use cases, 100% of PHI flows mapped, 100% of applicable vendors covered by appropriate agreements, and zero unowned production agents.

## Cost, budgets, and making the decision

AI vendor security has no universal market price because the cost depends on integration depth, data sensitivity, model hosting, assurance requirements, and the number of agents involved. A practical internal review may consume 40-120 staff hours for a moderate deployment when security, privacy, clinical safety, legal, procurement, and IT participate. A low-risk departmental pilot can sometimes be completed in 4-8 weeks, while a PHI-bearing or agentic production deployment may require 3-6 months of testing, contracting, and operational preparation. Independent penetration testing, clinical safety review, and model validation are usually quote-based and can move from tens of thousands of dollars to six figures for a broad engagement. These are planning ranges, not vendor prices, and should be adjusted to the organization's scope.

Cost should include more than the subscription. Include integration, identity and logging work, model or feature evaluation, red-team testing, privacy review, safety monitoring, incident exercises, contract review, and exit preparation. A cheap assistant that requires extensive manual review may be more expensive than a higher-priced service with usable audit trails, and a lower-cost model with a broad retrieval scope may create disproportionate review workload. Avoid financing decisions that hide ongoing monitoring in an implementation fee. The research context notes that vendor financing has become prominent in AI infrastructure build-outs, so healthcare buyers should examine the provider's financial condition, concentration risk, and ability to support the service during disruption rather than looking only at the initial quote.

The final decision should state what the system will do, what it will not do, who owns the residual risk, and what evidence will trigger a reassessment. A B2B healthcare hygiene, compliance, and safety-ops platform such as hygiea.tech can help organize vendor records, evidence requests, approvals, incidents, and recurring review dates, but it cannot replace a technical test, a clinically informed risk assessment, or legal advice. The strongest healthcare AI deployments are not the least regulated ones; they are the ones where the organization can explain the vendor's access, verify its safeguards, observe its behavior, and stop it quickly when the assumptions change. As of 24 September 2026, that evidence-based approach is more defensible than treating AI adoption itself as evidence of security maturity.

## Quick answers

### Does a SOC 2 report prove that a healthcare AI vendor is HIPAA compliant?

No. A SOC 2 Type II report provides independent assurance about selected controls over a defined period, but it is not a HIPAA certification and may not cover the specific AI service. Healthcare buyers still need to map data flows, determine business-associate status, sign appropriate agreements, and test the actual deployment.

### What is the most important security control for an autonomous healthcare AI agent?

The most important control is tightly scoped, revocable identity with least-privilege access to tools and data. An agent should not inherit a clinician's full access or use a shared permanent service account. Short-lived credentials, action approvals, audit logs, and a tested shutdown mechanism are especially important when the agent can change records or send communications.

### How often should healthcare organizations review AI vendors?

Review before production use, when a material model, hosting arrangement, subprocessor, or integration changes, and at least annually for ordinary services. Higher-risk agentic systems may need quarterly reviews or continuous monitoring. The review frequency should reflect the potential for patient harm, the sensitivity of the data, and the number of systems that depend on the vendor.

### Can a healthcare organization use an AI vendor that does not store patient data?

Not storing data can reduce retention risk, but it does not eliminate privacy or security obligations. Prompts, logs, tickets, retrievals, model inputs, and tool calls may contain protected information, and an agent may still cause unauthorized actions. The organization must verify the full data path and the vendor's contractual and technical controls rather than relying on the phrase no storage.

### What evidence should be requested before an AI vendor receives electronic health record access?

Request a data-flow diagram, system and agent architecture, subprocessor list, access-control design, encryption and key-management details, retention policy, logging examples, incident-response commitments, and appropriate contractual agreements. Ask for a demonstration that access is limited by role and purpose, and test that the vendor can revoke the integration without leaving active credentials behind.

Canonical: https://hygiea.tech/knowledge/which_ai_vendor_security_checks_should_healthcare_teams_require_in_2026.php
Markdown: https://hygiea.tech/knowledge/which_ai_vendor_security_checks_should_healthcare_teams_require_in_2026.php/index.md